REG - Hikma Pharmaceutical - Director/PDMR Shareholding
Hikma Pharmaceuticals PLC
Notification and public disclosure of transactions by persons discharging managerial responsibilities
Said Darwazah
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Said Darwazah
2
Reason for the notification
a)
Position/status
Executive Chairman
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Hikma Pharmaceuticals PLC
b)
LEI
549300BNS685UXH4JI75
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Description: Ordinary shares of 10 pence each (Shares)
ID Code: GB00B0LCW083
b)
Nature of the transaction
Conditional Shares acquired from the grant made on 13 April 2017 and vested on 14 April 2020 under the 2014 EIP Element C.
c)
Price(s) and volume(s)
Price(s): £nil
Volume(s): 36,438
d)
Aggregated information
N/A
e)
Date of the transaction
15 April 2020
f)
Place of the transaction
London Stock Exchange (XLON)
Mazen Darwazah
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Mazen Darwazah
2
Reason for the notification
a)
Position/status
Executive Vice Chairman
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Hikma Pharmaceuticals PLC
b)
LEI
549300BNS685UXH4JI75
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Description: Ordinary shares of 10 pence each (Shares)
ID Code: GB00B0LCW083
b)
Nature of the transaction
Conditional Shares acquired from the grant made on 13 April 2017 and vested on 14 April 2020 under the 2014 EIP Element C.
c)
Price(s) and volume(s)
Price(s): £nil
Volume(s): 19,318
d)
Aggregated information
N/A
e)
Date of the transaction
15 April 2020
f)
Place of the transaction
London Stock Exchange (XLON)
Majda Labadi
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Majda Labadi
2
Reason for the notification
a)
Position/status
PDMR
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Hikma Pharmaceuticals PLC
b)
LEI
549300BNS685UXH4JI75
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Description: Ordinary shares of 10 pence each (Shares)
ID Code: GB00B0LCW083
b)
Nature of the transaction
Conditional Shares acquired from the grant made on 13 April 2017 and vested on 14 April 2020 under the 2014 EIP Element C.
c)
Price(s) and volume(s)
Price(s): £nil
Volume(s): 16,146
d)
Aggregated information
N/A
e)
Date of the transaction
15 April 2020
f)
Place of the transaction
London Stock Exchange (XLON)
Riad Mishlawi
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Riad Mishlawi
2
Reason for the notification
a)
Position/status
PDMR
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Hikma Pharmaceuticals PLC
b)
LEI
549300BNS685UXH4JI75
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Description: Ordinary shares of 10 pence each (Shares)
ID Code: GB00B0LCW083
b)
Nature of the transaction
Conditional Shares acquired from the grant made on 13 April 2017 and vested on 14 April 2020 under the 2014 EIP Element C.
c)
Price(s) and volume(s)
Price(s): £nil
Volume(s): 20,146
d)
Aggregated information
N/A
e)
Date of the transaction
15 April 2020
f)
Place of the transaction
London Stock Exchange (XLON)
Bassam Kanaan
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Bassam Kanaan
2
Reason for the notification
a)
Position/status
PDMR
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Hikma Pharmaceuticals PLC
b)
LEI
549300BNS685UXH4JI75
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Description: Ordinary shares of 10 pence each (Shares)
ID Code: GB00B0LCW083
b)
Nature of the transaction
Conditional Shares acquired from the grant made on 13 April 2017 and vested on 14 April 2020 under the 2014 EIP Element C.
c)
Price(s) and volume(s)
Price(s): £22.82
Volume(s): 23,233
d)
Aggregated information
Number of Shares: 23,233
Price: £530,177
e)
Date of the transaction
14 April 2020
f)
Place of the transaction
London Stock Exchange (XLON)
Khalid Nabilsi
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Khalid Nabilsi
2
Reason for the notification
a)
Position/status
PDMR
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Hikma Pharmaceuticals PLC
b)
LEI
549300BNS685UXH4JI75
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Description: Ordinary shares of 10 pence each (Shares)
ID Code: GB00B0LCW083
b)
Nature of the transaction
Conditional Shares acquired from the grant made on 13 April 2017 and vested on 14 April 2020 under the 2014 EIP Element C.
c)
Price(s) and volume(s)
Price(s): £22.82
Volume(s): 23,751
d)
Aggregated information
Number of Shares: 23,751
Price: £541,998
e)
Date of the transaction
14 April 2020
f)
Place of the transaction
London Stock Exchange (XLON)
Susan Ringdal
a)
Name
Susan Ringdal
2
Reason for the notification
a)
Position/status
PDMR
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Hikma Pharmaceuticals PLC
b)
LEI
549300BNS685UXH4JI75
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Description: Ordinary shares of 10 pence each (Shares)
ID Code: GB00B0LCW083
b)
Nature of the transaction
Shares acquired from the exercise of nil-cost options granted on 17 May 2013 and 11 June 2014 under the 2007 LTIP and nil-cost options granted on 10 April 2015 under the 2014 EIP Elements B and C
c)
Price(s) and volume(s)
Share Plan
Price
Volume
2013 LTIP
£22.82
18,424
2014 LTIP
£22.82
11,774
2015 EIP B
£22.82
6,006
2015 EIP C
£22.82
6,006
d)
Aggregated information
Number of Shares: 42,210
Price: £963,232
e)
Date of the transaction
15 April 2020
f)
Place of the transaction
London Stock Exchange (XLON)
Brian Hoffmann
a)
Name
Brian Hoffmann
2
Reason for the notification
a)
Position/status
PDMR
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Hikma Pharmaceuticals PLC
b)
LEI
549300BNS685UXH4JI75
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Description: Ordinary shares of 10 pence each (Shares)
ID Code: GB00B0LCW083
b)
Nature of the transaction
Shares acquired from the vesting of nil-cost options granted on 11 May 2016 and 13 April 2017 under the 2014 EIP Element B.
c)
Price(s) and volume(s)
Share Plan
Price
Volume
2016 EIP B
£22.34
8,230
2017 EIP B
£22.34
9,327
d)
Aggregated information
Number of Shares: 17,557
Price: £392,223
e)
Date of the transaction
16 April 2020
f)
Place of the transaction
London Stock Exchange (XLON)
a)
Name
Brian Hoffmann
2
Reason for the notification
a)
Position/status
PDMR
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Hikma Pharmaceuticals PLC
b)
LEI
549300BNS685UXH4JI75
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Description: Ordinary shares of 10 pence each (Shares)
ID Code: GB00B0LCW083
b)
Nature of the transaction
Disposal of Shares.
c)
Price(s) and volume(s)
Price(s): £22.79
Volume(s): 2,219
d)
Aggregated information
Number of Shares: 2,219
Price: £50,571
e)
Date of the transaction
14 April 2020
f)
Place of the transaction
London Stock Exchange (XLON)
Peter Speirs
Company Secretary, responsible for releasing this announcement
16 April 2020
+44 (0) 20 7399 2760
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDDSHBSGDSUGBDGGL
Recent news on Hikma Pharmaceuticals
See all newsREG - Hikma Pharmaceutical - Result of AGM
AnnouncementREG - Hikma Pharmaceutical - Trading Statement
AnnouncementREG - Hikma Pharmaceutical - Director/PDMR Shareholding
AnnouncementREG - Hikma Pharmaceutical - Hikma appoints new President of Generics business
AnnouncementREG - Hikma Pharmaceutical - Director/PDMR Shareholding
Announcement